Hyperthermia syndromes in psychiatry

Advances in Psychiatric Treatment

Volumn 15, Issue 3, 2009, Pages 181-191

  Ahuja, Niraj ^a,b,c   Cole, Andrew J ^a,b  

^a TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Sir GB Hunter Memorial Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; CYPROHEPTADINE; DANTROLENE; DOPAMINE RECEPTOR; FRUCTOSE BISPHOSPHATE ALDOLASE; LORAZEPAM; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BASAL GANGLION; CATATONIA; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINERGIC SYSTEM; DRUG MEGADOSE; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HEAT STROKE; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; HYPERTHERMIA; HYPONATREMIA; INCIDENCE; LEUKOCYTOSIS; MALIGNANT HYPERTHERMIA; MENTAL DISEASE; METABOLIC ACIDOSIS; MORTALITY; MUSCLE BIOPSY; MYDRIASIS; MYOGLOBINURIA; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PATHOPHYSIOLOGY; RECOMMENDED DRUG DOSE; RISK FACTOR; SEROTONIN SYNDROME;

EID: 68949200456     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.107.005090     Document Type: Article

References (70)

1. Abbott RJ, Loizou LA (1986) Neuroleptic malignant syndrome. British Journal of Psychiatry; 148: 47-51.
2. Abrams R, Taylor MA (1976) Catatonia. A prospective clinical study. Archives of General Psychiatry; 33: 579-81.
3. Adityanjee, Singh S, Singh G, et al (1988) Spectrum concept of neuroleptic malignant syndrome. British Journal of Psychiatry; 153: 107-11.
4. Adityanjee (1991) The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. British Journal of Psychiatry; 158: 706-7.
5. Adityanjee, Mathews T, Aderibigbe YA (1999) Proposed research diagnostic criteria for neuroleptic malignant syndrome. International Journal of Neuropsychopharmacology; 2: 129-44.
6. Ahuja N, Nehru R (1990) Neuroleptic malignant syndrome: a subtype of lethal catatonia? Acta Psychiatrica Scandinavica; 92: 398.
7. Ahuja N (2000) Organic catatonia. Indian Journal of Psychiatry; 42: 327-46.
8. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revised (DSM-IV-TR). APA.
9. Ayd FJ (1956) Fatal hyperpyrexia during chlorpromazine treatment. Journal of Clinical and Experimental Psychopathology and Quarterly Review of Psychiatry and Neurolology; 17: 189-92.
10. Billig O, Freeman WT (1944) Fatal catatonia. American Journal of Psychiatry; 100: 633-8.
11. Boyer EW, Shannon M (2005) The serotonin syndrome. New England Journal of Medicine; 352: 1112-20.
12. Bush G, Fink M, Petrides G, et al (1996) Catatonia. I. Rating scale and standardized examination. Acta Psychiatrica Scandinavica; 93: 129-36.
13. Caroff S, Rosenberg H, Gerber JC (1983) Neuroleptic malignant syndrome and malignant hyperpyrexia. Lancet; I: 244.
14. Caroff SN, Mann SC (1988) Neuroleptic malignant syndrome. Psychopharmacology Bulletin; 24: 25-9.
15. Caroff SN, Mann SC (1993) Neuroleptic malignant syndrome. Medical Clinics of North America; 77: 185-202.
16. Caroff SN, Mann SC, Campbell EC (2000) Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals; 30: 314-21.
17. Caroff SN, Rosenberg H, Mann SC, et al (2001) Neuroleptic malignant syndrome in the perioperative setting. American Journal of Anesthesiology; 28: 387-93.
18. Carroll BT, Goforth HW (1995) Serum iron in catatonia. Biological Psychiatry; 38: 776-7.
19. Chopra MP, Prakash SS, Raguram R (1999) The neuroleptic malignant syndrome: an Indian experience. Comprehensive Psychiatry; 40: 19-23.
20. Delay J, Pichot P, Lemperiere MT, et al (1960) Un neuroleptique majaeur non-phenothiazineque et non reserpinique, l'halidol, dans le traitment des psychoses. Annales Médico-Psychologiques; 118.
21. Delay J, Deniker P (1968) Drug induced extrapyramidal syndromes. In Handbook of Clinical Neurology, Volume 6: Diseases of the Basal Ganglia (eds PJ Vinken, GW Bruyn): 248-66. North-Holland.
22. Denborough MA, Lovell RRH (1960) Anaesthetic deaths in a family. Lancet; ii: 45.
23. Deng MZ, Chen GQ, Phillips MR (1990) Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. American Journal of Psychiatry; 147: 1149-55.
24. Dharmarajan TS, Bullecer MF, Gorich G (2001) Drug-related hyperthermia. Journal of the American Medical Directors Association; 2: 160-5.
25. Dunkley EJC, Isbister GK, Sibbritt D, et al (2003) Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rule for serotonin toxicity. Quarterly Journal of Medicine; 96: 635-42.
26. Exton-Smith AN (1972) Phenothiazines in cold weather. BMJ; 1: 441.
27. Fink M, Taylor MA (2003) Catatonia: A Clinician's Guide to Diagnosis and Treatment. Cambridge University Press.
28. Gelenberg AJ (1976) The catatonic syndrome. Lancet; 1: 1339-41.
29. Gurrera RJ, Simpson JC, Tsuang MT (2007) Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Comprehensive Psychiatry; 48: 205-11.
30. Hasan S, Buckley P (1998) Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. American Journal of Psychiatry; 155: 1113-6.
31. Hoagland RJ, Bishop RH Jr (1961) A physiologic treatment of heat stroke. American Journal of Medical Sciences; 241: 415-22.
32. Hynes AF, Vickar EL (1996) Case study: neuroleptic malignant syndrome without pyrexia. Journal of American Academy of Child and Adolescent Psychiatry; 35: 959-62.
33. Insel TR, Roy BF, Cohen RM, et al (1982) Possible development of the serotonin syndrome in man. American Journal of Psychiatry; 139: 954-5.
34. Isbister GK, Buckley NA, Whyte IM (2007) Serotonin: a practical approach to diagnosis and treatment. Medical Journal of Australia; 187: 361-5.
35. Jauss M, Krack P, Franz M, et al (1996) Imaging of dopamine receptors with [123I]Iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Movement Disorders; 11: 726-8.
36. Keck PE Jr, Pope HG, McElroy SL (1991) Declining frequency of neuroleptic malignant syndrome in a hospital population. American Journal of Psychiatry; 148: 880-2.
37. Kellam AMP (1987) The neuroleptic malignant syndrome, so-called. A survey of world literature. British Journal of Psychiatry; 150: 752-9.
38. Khaldarov V (2000) Benzodiazepines for treatment of neuroleptic malignant syndrome. Hospital Physician; 6: 51-5.
39. Koch M, Chandragiri S, Rizvi S, et al (2000) Catatonic signs in neuroleptic malignant syndrome. Comprehensive Psychiatry; 41: 73-5.
40. Lazarus A, Rosenberg H (1991) Malignant hyperthermia during ECT. American Journal of Psychiatry; 148: 541-2.
41. Levenson JL (1985) Neuroleptic malignant syndrome. American Journal of Psychiatry; 142: 1137-45.
42. Levinson DF, Simpson GM (1986) Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the 'neuroleptic malignant syndrome'. Archives of General Psychiatry; 43: 839-48.
43. Mackay FJ, Dunn NR, Mann RD (1999) Antidepressants and the serotonin syndrome in general practice. British Journal of General Practice; 49: 871-4.
44. Mann SC, Caroff SN, Bleier HR, et al (1986) Lethal catatonia. American Journal of Psychiatry; 143: 1374-81.
45. Mann SC, Caroff SN (1987) Neuroleptic malignant syndrome and lethal catatonia. American Journal of Psychiatry; 144: 1370.
46. Mann SC, Caroff SN, Keck PE, et al (2003) Neuroleptic Malignant Syndrome and Related Disorders (2nd edn). American Psychiatric Publishing.
47. McDaniel WW (2001) Serotonin syndrome: early management with cyproheptadine. Annals of Pharmacotherapy; 35: 870-3.
48. McGugan EA (2001) Hyperpyrexia in the emergency department. Emergency Medicine; 13: 116-20.
49. Meltzer HY, Ross-Santon J, Schelssinger S (1980) Mean serum creatinine kinase activity in patients with functional psychoses. Archives of General Psychiatry; 37: 650-5.
50. Mitchell RS (1955) Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Annals of Internal Medicine; 42: 417-24.
51. Mizuno Y, Takubo H, Mizuta E, et al (2003) Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism and Related Disorders; 9 (suppl 1): S3-9.
52. Montoya A, Ocampo M, Torres-Ruiz A (2003) Neuroleptic malignant syndrome in Mexico. Canadian Journal of Clinical Pharmacology; 10: 111-3.
53. Nehru R, Ahuja N (2002) Catatonia following acute dopamine depletion. Journal of Neuropsychiatry and Clinical Neurosciences; 14: 107.
54. Oates JA, Sjoerdsma A (1960) Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology; 10: 1076-8.
55. Osman AA, Khurasani MH (1994) Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut-down hypothesis. British Journal of Psychiatry; 165: 548-50.
56. Otani K, Horiuchi M, Kondo T, et al (1991) Is the predisposition to neuroleptic malignant syndrome genetically transmitted? British Journal of Psychiatry; 158: 850-3.
57. Rajagopal S (2007) Catatonia. Advances in Psychiatric Treatment; 13: 51-9.
58. Reulbach U, Bleich S (2005) Managing an effective treatment for neuroleptic malignant syndrome. European Neuropsychopharmacology; 15: S518.
59. Reulbach U, Dütsch C, Biermann T, et al (2007) Managing an effective treatment for neuroleptic malignant syndrome. Critical Care; 11: R4, 1-6.
60. Rosebush P, Stewart T (1989a) A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry; 146: 717-25.
61. Rosebush PI, Stewart TD, Gelenberg AJ (1989b) Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. Journal of Clinical Psychiatry; 50: 295-8.
62. Sachdev P, Kruk J, Kneebone M, et al (1995) Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. Journal of Clinical Psychopharmacology; 15: 365-71.
63. Stauder KH (1934) Die todliche katatonia [Lethal catatonia]. Archiv fur Psychiatric und Nervenkrankheiten; 102: 614-34 (trans & reprinted in Ungvari GS (ed) (2006) Catatonia: An Anthology of Classical Contributions, pp 104-33. Scientific Communications International).
64. Sternbach H (1991) The serotonin syndrome. American Journal of Psychiatry; 148: 705-13.
65. Troller JN, Sachdev PS (1999) Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Australian and New Zealand Journal of Psychiatry; 33: 650-9.
66. Ueda M, Hamamoto M, Nagayama H, et al (2001) Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome. Journal of Neurology, Neurosurgery and Psychiatry; 71: 111-3.
67. White DA (1992) Catatonia and the neuroleptic malignant syndrome - a single entity? British Journal of Psychiatry; 161: 558-60.
68. Woodbury MM, Woodbury MA (1992) Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. Journal of American Academy of Child and Adolescent Psychiatry; 31: 1161-4.
69. Yacoub A, Francis A (2006) Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatric Disease and Treatment; 2: 235-40.
70. Zarrouf FA, Bhanot V (2007) Neuroleptic malignant syndrome: don't let your guard down yet. Current Psychiatry; 6: 89-95.